Cellect Biotechnology Ltd (APOP) EPS Estimated At $-0.22

June 20, 2017 - By Marguerite Chambers

 Cellect Biotechnology Ltd (APOP) EPS Estimated At $ 0.22

Investors wait Cellect Biotechnology Ltd (TLV:APOP) to report on July, 7. its quarterly earnings Cellect Biotechnology Ltd’s Wall Street analysts see 2,100.00 % negative EPS growth, taking into account the $-0.01 EPS reproted in the previous quarter, About 51,876 shares traded. Cellect Biotechnology Ltd (TLV:APOP) has 0.00% since June 20, 2016 and is . It has underperformed by 16.70% the S&P500.

Cellect Biotechnology Ltd, formerly Cellect Biomed Ltd, is an Israel firm engaged in regenerative medicine through the development of products facilitating immune stem cell selection. The company has market cap of $154.00 million. The Company’s platform technology is based on the game changing perception that the functional properties of stem cells rather than appearance should be used for their identification, selection and utilization. It currently has negative earnings. The Company’s first product is designed to harness the critical function of sensitivity to specific apoptosis-inducing agents.

More notable recent Cellect Biotechnology Ltd (TLV:APOP) news were published by: Prnewswire.com which released: “Cellect Biotechnology Ltd Provides Corporate Update and Reports First Quarter …” on May 29, 2017, also Investorplace.com with their article: “Why Cellect Biotechnology Ltd. (APOP) Stock Is Soaring Today” published on March 27, 2017, Quotes.Wsj.com published: “Cellect Biotechnology Ltd. ADR APOP (US: Nasdaq)” on July 29, 2016. More interesting news about Cellect Biotechnology Ltd (TLV:APOP) were released by: Fool.com and their article: “Why Cellect Biotechnology Ltd Shares Skyrocketed Higher Today” published on February 08, 2017 as well as Rttnews.com‘s news article titled: “Cellect Biotechnology Ltd. (APOP) Is Surging On Patent News” with publication date: January 12, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.